LOGIN  |  REGISTER
Terns Pharmaceuticals
Cue Biopharma

Regional Health Properties Announces Commencement of Trading of Series B Preferred Stock on OTC Markets

August 03, 2023 | Last Trade: US$2.77 0.00 0.00

ATLANTA, GA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company”) (NYSE American: RHE) (NYSE American: RHE-PA) (OTCQB Venture: RHEPB), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, announced today that its 12.5% Series B Cumulative Redeemable Preferred Shares (the “Series B Preferred Stock”) commenced trading on the OTCQB Venture Market, operated by the OTC Markets Group, Inc., under the symbol “RHEPB”.

The Company’s Common Stock and Series A Redeemable Preferred Shares will continue to trade on the NYSE American LLC under the symbols “RHE” and “RHE-PA,” respectively. The Company will continue to file its required periodic reports and other filings with the Securities and Exchange Commission.

About Regional Health Properties

Regional Health Properties, Inc., a Georgia corporation, is a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care. For more information, visit www.regionalhealthproperties.com.

 
Company Contact
 

Brent Morrison, CFA
Chief Executive Officer & President
Regional Health Properties, Inc.
Tel (678) 368-4402
This email address is being protected from spambots. You need JavaScript enabled to view it.

Viking Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page